Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of NPH insulin and insulin lispro is a treatment regimen used for diabetes management that pairs an intermediate-acting insulin (NPH) with a rapid-acting insulin analog (insulin lispro). ## Description NPH insulin + insulin lispro is a combination therapy used in the treatment of both type 1 and type 2 diabetes mellitus. This regimen combines NPH (Neutral Protamine Hagedorn) insulin, an intermediate-acting insulin, with insulin lispro (brand name Humalog), a rapid-acting insulin analog. The combination provides both immediate and extended glucose control. Insulin lispro works rapidly, with onset within 15-30 minutes and peak action within 30-90 minutes, making it ideal for mealtime coverage. NPH insulin has a slower onset (2-4 hours) and longer duration (12-18 hours), providing basal insulin coverage between meals and overnight[1][2]. Studies have shown that using insulin lispro with NPH insulin in a twice-daily regimen allows injection closer to mealtime and improves post-prandial glycemic control without increasing hypoglycemia risk[1]. The combination has demonstrated better overall blood glucose control in type 1 diabetic patients compared to regular human insulin with NPH[2]. ## Administration When mixing these insulins: - Insulin lispro should be drawn into the syringe first, followed by NPH insulin[3][6] - Injection should occur immediately after mixing[3][6] - The combination is typically administered in a twice-daily regimen[1] This combination is not pre-mixed commercially but is prepared by the patient or healthcare provider at the time of administration. The mixing order is important to prevent potential compatibility issues. ## Benefits The primary advantages of this combination include: - Improved postprandial glucose control compared to regular insulin + NPH[1][2] - Ability to inject closer to mealtime due to insulin lispro's rapid onset[1] - Better overall glycemic control as measured by HbA1c levels[2] - Similar or reduced risk of hypoglycemia compared to regular insulin + NPH[1][2] - Greater patient acceptance and treatment satisfaction[2] ## Considerations For optimal use of this combination: - The timing between meals should be considered, as insulin lispro's shorter duration may lead to hyperglycemia if meals are spaced too far apart[8] - Additional doses of NPH may be needed at lunch to meet basal insulin requirements between meals if dinner is eaten late[8] - Patients with unpredictable eating habits may benefit from insulin lispro's flexibility, as it can be timed with meals[8] This combination represents an important treatment option for diabetes management, offering improved glycemic control with the convenience of mealtime dosing flexibility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NPH insulin + insulin lispro.